Stock comparison
Moderna, Inc. is 8.7x more valuable than Adaptive Biotechnologies Corp by market capitalization ($30.38 B vs $3.49 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 8.7x more valuable than Adaptive Biotechnologies Corp by market capitalization ($30.38 B vs $3.49 B).
Market value leader
MRNA
Moderna, Inc. is 8.7x more valuable than Adaptive Biotechnologies Corp by market capitalization ($30.38 B vs $3.49 B).
Revenue leader
MRNA
ADPT: $276.98M vs MRNA: $1.94B.
Profit leader
ADPT
ADPT: -$59.50M vs MRNA: -$2.82B.
Margin leader
ADPT
ADPT: -21.5% vs MRNA: -145.2% net margin.
| Metric | ADPT | MRNA |
|---|---|---|
| Market cap | $3.49 B | $30.38 B |
| US-listed rank | #1710 | #461 |
| Revenue (latest FY) | $276.98M | $1.94B |
| Net income (latest FY) | -$59.50M | -$2.82B |
| Net margin | -21.5% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 764 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 8.7x more valuable than Adaptive Biotechnologies Corp by market capitalization ($30.38 B vs $3.49 B).
In their latest fiscal years, Adaptive Biotechnologies Corp reported $276.98M in revenue while Moderna, Inc. reported $1.94B.
Full pages: Adaptive Biotechnologies Corp and Moderna, Inc., or browse the full rankings.